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Background: In this study, we developed a pharmacokinetic (PK)- pharmacodynamic (PD) model of a new sustained
release formulation of interferon-α-2a (SR-IFN-α) using the blood concentration of IFN-α and neopterin in order to
quantify the magnitude and saturation of neopterin production over time in healthy volunteers. The SR-IFN-α in this
study is a solid microparticular formulation manufactured by spray drying of a feeding solution containing IFN-α, a
biocompatible polymer (polyethylene glycol) and sodium hyaluronate.
Methods: The full PK and PD (neopterin concentration) datasets from 24 healthy subjects obtained after single doses
of 9, 18, 27 and 36 MIU of subcutaneous SR-IFN-α were used to build the mixed-effect model using NONMEM (version
7.2) with the GFORTRAN compiler.
Results: A one-compartment model with first-order elimination and a mixture of zero- and first-order absorption was
chosen to describe the PK of SR-IFN-α. The time-concentration profile of neopterin, the PD marker, was described by a
turnover model combined with a single transit compartment. The saturable pattern of the neopterin response blurring
the dose–response relationship of SR-IFN-α was addressed by introducing the concept of the EC50 increasing over time.
Conclusions: The PK-PD model of SR-IFN-α developed in this study has presented a quantitative tool to assess the
time-course of a saturable neopterin response in humans.
Keywords: PK-PD modeling, IFN-α, NONMEM, NeopterinBackground
Interferons are produced by peripheral blood leukocytes,
fibroblasts, and activated T and NK cells in response to
viral infection or other inducers including double-
stranded RNA, lipopolysaccharide, micro-organisms, or
endotoxins [1-3]. Based on immunological and physico-
chemical differences, human interferons are divided into
α-, β-, and γ-interferon families, with numerous subtypes
within each interferon family [4]. Because of its antiviral,
antiproliferative and immunomodulating properties, re-
combinant interferon-α (IFN-α) has been used as a
treatment for various diseases [5]. However, in the case* Correspondence: yimds@catholic.ac.kr
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reproduction in any medium, provided the orof chronic hepatitis C, monotherapy with IFN-α has
been persistently effective in only a small percentage of
patients [6]. This low response rate is thought to be due
to HCV genotype variation and/or the quite short half-
life of IFN-α [7,8]. Combination therapy with other anti-
viral agents, such as ribavirin, is therefore recommended
[9]. Frequent administration (3 times weekly) of IFN-α
has been considered to be an additional cause for thera-
peutic failure of interferon due to the fact that frequent
administration accelerates the formation of neutralizing
antibodies and causes other adverse effects due to large
variations in peak-to-trough plasma drug concentrations
[10,11]. Hence, a long-acting formulation has been de-
veloped for IFN-α which can extend its effects to weeks
and months.
Unlike small molecule drugs, the poor stability of pro-
tein drugs has been a hurdle to the development of longd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long-acting formulations of protein drugs can be roughly
classified into chemical modification such as pegylation
[13] or formulation changes allowing delayed release
from depot sites. The new sustained release formulation
of IFN-α-2a (SR-IFN-α, LG Life Sciences) used in our
report is a solid microparticular formulation manufactured
by the spray drying of a feeding solution containing IFN-α,
a biocompatible polymer (polyethylene glycol) and sodium
hyaluronate [14].
This report is based upon a first-in-human, single as-
cending dose trial of SR-IFN-α in healthy volunteers
where the IFN-α concentration profile showed an
extended release pattern through the doses studied.
Blood neopterin concentrations were also measured as a
biomarker demonstrating the activity of IFN-α in this
first-in-human study. Neopterin is a soluble immune ac-
tivation marker released from monocytes and macro-
phages by IFN-α [15]. Looking into the relationship
between the exposure to IFN-α and neopterin in the
healthy subjects’ data, we found that the magnitude of
neopterin concentration changes was not clearly corre-
lated with the dose of IFN-α. Although similar phenom-
ena have been observed in animal experiments [16,17],
this has never been reported in humans despite frequent
clinical trials using neopterin as a biomarker. Because
clear understanding of the relationship between exposure
and response is one of the fundamental goals of early-
phase exploratory clinical trials, we investigated the
concentration-response relationship of IFN-α and neopterin
in humans, which has never been elucidated. As results,
we present a pharmacokinetic-pharmacodynamic (PK-PD)
model that quantifies the peculiar time-course of
neopterin responses to IFN-α in humans.
Methods
Inclusion and exclusion criteria
Healthy volunteers aged 18 to 45 years with BMI ran-
ging from 19 to 29 kg/m2, with no clinically relevant
conditions identified based on medical history, physical
examination, laboratory tests or electrocardiography
(ECG), were eligible for inclusion. Subjects with any history
that indicated a possible alteration in IFN-α metabolismTable 1 Subject demographicsa
Group Control 1
Dose 3 MIU 9 MIU
Number of Subjects 8 6
Sex Male Male
Age (years) 24.0 (18 ~ 43) 21.5 (19 ~ 37)
Height (cm) 181.65 (165.5 ~ 189.0) 179.05 (171.0 ~ 191.5)
Weight (kg) 73.85 (69.0 ~ 82.2) 78.65 (60.3 ~ 92.4)
aContinuous variables are shown as median (range).or with hypersensitivity to IFN-α were excluded. The final
study enrollment was 32 subjects (Table 1).
Study design
A randomized, double-blind, active controlled, dose es-
calation phase I clinical study was conducted on 32
healthy subjects in the clinical pharmacology unit of the
Kendle International BV, located in Utrecht, Netherlands.
Subjects were randomly allocated into four groups (eight
subjects per group). Within each group, six were given
SR-IFN-α (test formulation) and the other two were given
3 MIU Roferon-A® (Roche, active comparator) via sub-
cutaneous injection. The doses of SR-IFN-α allocated to
groups 1, 2, 3 and 4 were 9 MIU, 18 MIU, 27 MIU, and 36
MIU, respectively.
The study was performed in compliance with the
European Community rules of Good Clinical Practice
(GCP), the International Conference on Harmonization
(ICH) Tripartite Guidelines: Guideline for GCP, the current
revision of the ‘Declaration of Helsinki’ (Edinburgh,
amendment October 2000). The Stichting Therapeutische
Evaluatie Geneesmiddelen (STEG), an independent ethics
committee, approved the protocol before execution of the
trial, and all participants gave written informed consent.
Blood sampling
For the population PK analysis, peripheral blood samples
(5 mL each) were taken just prior to the injection, and
0.75, 1.5, 3, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, 72, 96,
120, 144, 168, and 192 hours after the injection. For the
PD marker, the sampling times differed slightly: just
prior to the injection and 3, 8, 12, 18, 24, 36, 48, 72, 96,
120, 144, 168, 192, and 264 hours after the injection.
The samples were collected in light-protective tubes and
stored at < −70°C.
Assay of plasma concentrations of IFN-α and neopterin
IFN-α concentrations in the serum samples were ana-
lyzed using a commercial Human IFN-α Multi-Subtype
ELISA Kit (product # 41105) with a detection limit of
12.5 pg/mL manufactured by Pestka Biomedical Laborator-
ies, Inc. (Piscataway, NJ, USA). Neopterin concentrations
in the serum samples were analyzed using a commercially-2 3 4
18 MIU 27 MIU 36 MIU
6 6 6
Male Male Male
22 (19 ~ 34) 22 (18 ~ 42) 24 (20 ~ 43)
183.5 (172.0 ~ 187.0) 178.15 (168.0 ~ 191.5) 181.75 (178.0 ~ 193.0)
76.15 (63.0 ~ 86.5) 74.40 (53.8 ~ 92.6) 74.40 (70.7 ~ 98.8)
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GenWay Biotech, Inc., San Diego, CA, USA) with a detec-
tion limit of 0.7 nmol/L and the specificity of about
99.95%.
Population PK-PD model
Because the aim of this study was to develop a PK-PD
model for SR-IFN-α, data from the active control group
participants, who were given the immediate release IFN-
α formulation (8 subjects), were not included in the ana-
lysis (individual plots for PK-PD models are shown in
Additional file 1).
Mean plasma concentrations of IFN-α are shown in
Figure 1, and non-compartmental analysis results of the
PK of SR-IFN-α are summarized in Table 2. The popula-
tion PK-PD analysis was performed using NONMEM
(version 7.2, Icon Development Solutions, Ellicott City,
MD, USA) with the GFORTRAN compiler.
To find the model that best described the absorption
profile, which showed double peaks in many subjects,
first- and zero-order absorption models and their com-
bined form, with or without lag time, were tested. Based
on first-order elimination, one- and two-compartment
distribution models were tested for the three absorption
(first-order, zero-order and combined) processes. The
Michaelis-Menten absorption and elimination models
were also tested considering the potential saturable ab-
sorption or elimination using the ADVAN subroutines
(Table 3).
The coupling of the PK model to the PD model was
done in a sequential manner. The population PD model-
ing was performed using the individual PK parameters
estimated from the final PK model, which were added to
the PD dataset.Figure 1 Plasma concentration–time curves of interferon-α (Mean andTurnover models, with or without transit compart-
ments, were compared to find the most appropriate
model that explained the delayed effect of IFN-α on
neopterin concentrations. The turnover model was ini-
tially selected over the effect compartment model based
upon the well-known action of IFN-α stimulating the re-
lease of neopterin, and the transit compartments were
tested because their usefulness was reported in a previ-
ous preclinical study [16].
The differential equations for the drug effect model
(model structures are shown in Figure 2) were:
dA 1ð Þ
dt
¼ −Ka : A 1ð Þ
dA 2ð Þ
dt
¼ Ka : A 1ð Þ−Ke : A 2ð Þ
dA 3ð Þ
dt
¼ Kin : E Cð Þ−Ktr : A 3ð Þ
dA 4ð Þ
dt
¼ Ktr : A 3ð Þ−Kout : A 4ð Þ
where Ka and Ke are the absorption and elimination rate
constants for IFN-α, respectively. Kin is the production
rate of neopterin, a zero-order constant, Ktr is the first-
order transition rate leaving the transit compartment,
Kout is the first-order rate constant for the elimination of
neopterin, and E(C) is the effect as a function of the in-
dividual predicted drug concentration, C. A(4), which isS.D.).
Table 2 Non-compartmental analysis of interferon-α: Mean ± S.D. (CV%)
Group Dose Formulation Cmax (pg/mL) Median Tmax (h) AUClast (ng·h/mL)
Controla (N=8) 3 MIU Roferon-A® 43.27 ± 9.804 (22.66%) 6 0.9664 ± 0.9322 (96.46%)
1 (N=6) 9 MIU SR-IFN-α 28.33 ± 9.656 (34.08%) 18 2.072 ± 1.134 (54.73%)
2 (N=6) 18 MIU SR-IFN-α 62.12 ± 15.93 (25.64%) 24 5.373 ± 1.382 (25.72%)
3 (N=6) 27 MIU SR-IFN-α 65.73 ± 6.702 (10.20%) 24 5.544 ± 0.5509 (9.94%)
4 (N=6) 36 MIU SR-IFN-α 80.31 ± 9.859 (12.28%) 24 7.151 ± 1.132 (15.83%)
aThere was not a separate control group, but data from a total of eight subjects (two subjects in each of the four groups) who received 3 MIU of Roferon-A®
were shown.
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the concentration of neopterin.
The stimulatory function for the drug effect, E(C), was
a sigmoid function:
E Cð Þ ¼ 1þ Emax
: Cr
EC50r þ Cr
where Emax is the maximum effect and EC50 is the IFN-
α concentration that produces 50% of the maximum
effect.
In our study, differences in the mean plasma neopterin
concentrations between the groups receiving different
doses of SR-IFN-α were not clearly discernible (Figure 3).
To account for this phenomenon in our PD model, we
incorporated the concept of time-dependent attenuation
of the effect parameters [18], especially the increasing
EC50 over time, as shown in the following equation:
EC50 ¼ ECB 1þ CA 1−e−CBTIME
  
where ECB is the baseline of EC50 and CA and CB are
coefficients to describe the EC50 increase to a certain
level (ECB × CA) over time. This curve is the cumula-
tive distribution function (CDF) of an exponential distri-
bution to EC50. It has advantages in explaining the
concave-shaped curves in relation to time.
The first-order conditional estimation (FOCE) method
with interaction was used throughout the model build-
ing. Models were selected based upon a decrease in theTable 3 PK model development process
Step Model testeda
1 One-compartment model with first-ord
One-compartment model with first-order abso
2 Two-compartment model with first-ord
Two-compartment model with first-order abso
Two-compartment model with saturable absorption (M
3 Two-compartment model with zero-ord
4 One-compartment model with a mixture of zero a
One-compartment model with Michaelis Menten elimination and a
aThe elimination process was assumed to follow first-order kinetics.objective function value (OFV) of more than 3.84 (P-value
0.05 in an approximate χ2 distribution) and improvement
in the individual plots, as well as other scatterplots.
A log normal distribution was assumed for inter-
individual variability (η), and PK or PD parameters of
the jth subject (Pj) were described as:
Pj ¼ TVP  exp ηj
 
where TVP represents the typical population value of
PK-PD parameters, such as clearance (CL), volume of
distribution (V), absorption rate constant (Ka), lag time
(ALAG), the first-order elimination rate of serum
neopterin (Kout), and maximum stimulation effect (Emax).
The inter-individual variability eta (η) for each PK-PD par-
ameter was assumed to follow a Gaussian distribution
with a mean 0 and a variance ω2. Possible correlations be-
tween the inter-individual variability were also evaluated.
As for the residual error, the additive, proportional
and combined forms were tested. An example of the
combined error form is shown as follows:
Y ij ¼ IPREDij þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
εadd;ij2 þ εprop;ij  IPREDij
 2q
where IPREDij is the individual predicted concentration,
Yij is the measured concentration of the jth individual at
the ith sampling time, and εij is residual error. Residual
errors (ε) include intra-individual variability, assay
error and model misspecification. They were alsoObjective function value
er absorption 2138.416
rption (with lag-time) 2130.609
er absorption 2037.527
rption (with lag-time) 1993.071
ichaelis Menten absorption) 2140.583
er absorption 1885.795
nd first-order absorption 1879.067














1) 0<time<D2 : zero-order input (Fz·F·Dose) 
2) From time ALAG : first-order input ((1-Fz)·F·Dose)
: Stimulatory effect attenuated by time 
Figure 2 PK-PD model structure. The mixed absorption with one-
compartment first-order elimination model (PK) and the turnover
model with a single transit compartment (PD) are shown.
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and variance σ2.
Covariate selection
Age, height, weight and creatinine clearance were
screened as potential covariates of the parameters using
Generalized Additive Modeling (GAM) implemented by
Xpose version 4.2.3.
In the forward selection of covariates, variables that
decreased the OFV by more than 3.84 (P < 0.05) and im-
proved the inter-individual variability (omega value de-
crease) were selected. Covariates that did not increase
the OFV more than 3.84 (P < 0.05) in the backward


























Figure 3 Plasma neopterin concentration changes in response to inte
injection of Roferon-A® or SR-IFN-α show little difference between dose groModel evaluation
The 95% confidence intervals (CIs) for mean population
PK and PD parameters were determined using a re-
sampling technique based on the bootstrap method.
One thousand re-sampled datasets were collected and
their parameters were estimated using our population
models. The models were also evaluated by visual pre-
dictive checks (VPC) using 1,000 simulated datasets.
Results
Population PK-PD model
The results of non-compartmental PK analysis showing
the trend of PK linearity of SR-IFN-α are briefly summa-
rized in Table 2. A one-compartment model with first-
order elimination and a mixture of zero- and first-order
absorption best described the PK of SR-IFN-α. The de-
layed pattern of the time-concentration profile of
neopterin was well described by the turnover model with
a single transit compartment. There was no significant
covariate. The structure of the final PK-PD model is
shown in Figure 2. The population PK-PD parameter es-
timates, with corresponding standard error (SE) values,
are summarized in Table 4. Basic goodness-of-fit plots
are presented in Figure 4. Predicted concentration-time
profiles of IFN-α and observed data from representative
individuals are shown in Figure 5.
Model evaluation
The 95% confidence intervals (CIs) for population PK-
PD parameter estimates, determined using the bootstrap
re-sampling method, are shown in Table 4. VPC plots
simulated concentrations of 1,000 virtual datasets144 168 192 216 240 264
e (h)
erin





rferon-α (Mean and S.D.). Plasma neopterin concentrations after
ups.
Table 4 Final estimates of population PK-PD parameters
Parameter Description Estimate %RSE Bootstrap median (95% CI)a
Pharmacokinetics
CL/F (L/h) Apparent clearance 12.2 7.39 12.5 (4.9~14.9)
V/F (L) Apparent volume of distribution 691 6.54 712 (324~980)
D2 (h) Duration of zero-order absorption 20.2 7.08 19.9 (16.6~23.0)
KA (h-1) Absorption rate constant of first-order absorption 0.00653 16.23 0.00721 (0.0010~0.1715)
ALAG (h) Lag time to the initiation of first-order absorption 85.7 3.92 88.1 (80.9~108.0)
RFb Alternate variable for relative fraction absorbed in zero-order absorption process 0.185 55.68 0.24 (−1.17~0.94)
ωCL (%) Between subject variability of CL 26.1 35.1 24.5 (14.4~32.7)
ωV (%) Between subject variability of V 23.8 58.0 23.7 (0.4~37.6)
ωD2 (%) Between subject variability of D2 35.7 27.1 34.8 (23.0~49.4)
ωRF (%) Between subject variability of RF 34.7 64.1 32.1 (0.3~54.2)
ωka (%) Between subject variability of KA 77.0 37.1 59.5 (0.7~95.4)
σadd (pg/mL) Additive error 3.92 12.65 3.83 (−3.36~4.80)
σprop (%) Proportional error 7.8 26.06 7.0 (−8.8~11.9)
Pharmacodynamics
BASE (nmol/L) Baseline of neopterin 5.85 4.17 5.88 (5.39~6.34)
KOUT (h-1) First-order elimination rate of serum neopterin 0.0311 17.20 0.03 (0.02~0.04)
EMAX Maximum stimulatory effect 16.1 53.19 17.45 (7.06~62.42)
GA Hill coefficient (γ) 1.24 11.85 1.27 (1.01~2.52)
CAc Coefficient 405 115.80 616.5 (27~13115)
CBc Coefficient 0.0068 27.73 0.0064 (0.0014~0.0119)
ECBc Baseline of EC50 2.17 152.07 1.66 (0.05~74.67)
MTT (h) Mean transit time 14.6 11.37 14.5 (9.82~19.2)
ωBASE (%) Between subject variability of BASE 13.85 51.84 12.63 (3.91~20.79)
ωCB (%) Between subject variability of CB 57.31 43.31 46.21 (0.32~72.61)
ωGA (%) Between subject variability of GA 13.51 55.80 13 (0.32~36.49)
ωECB (%) Between subject variability of ECB 21.31 172.97 21.39 (0.45~55.86)
ωMTT (%) Between subject variability of MTT 13.36 94.92 10.75 (0.55~24.21)
σadd (nmol/L) Additive error 1.14 11.05 1.11 (0.95~1.37)
a95% CIs obtained from estimation of 1000 bootstrap-resampled datasets; bFraction absorbed in zero-order absorption, Fz = e
RF/(1+ eRF); Fraction absorbed in first-
order absorption: 1-Fz;
cEC50 =ECB*(1+CA*(1-e-CB*Time)); RSE Relative standard error.
Jeon et al. Journal of Translational Medicine 2013, 11:240 Page 6 of 9
http://www.translational-medicine.com/content/11/1/240(nsub=1000 in the $SIMULATION block, 24,000 virtual
patients) from the final model. The results from the
VPC showed that the PK-PD model gave acceptable pre-
dictive performance. Curves for the 12.5th, 50th and
87.5th percentiles of concentrations were overlaid on the
observed concentrations (Figure 6).
Discussion
In this study, we presented results of PK-PD modeling of
the time-concentration profiles of IFN-α and neopterin
after administration of SR-IFN-α in healthy subjects.
For PK characteristics, the combined absorption
model was successful in describing the double peak
phenomenon. A zero-order absorption model appropri-
ately described the initial increase in concentration, asmeasured by relatively frequent sampling, before
reaching the maximum concentration. Subsequent sec-
ond peaks (observed around 100 h after injection) were,
however, best described by a first-order absorption
model. One possible explanation for this double-peak
phenomenon is in the method of SR-IFN-α administra-
tion: SR-IFN-α should be mixed with medium chain tri-
glycerides (MCT) right before subcutaneous injection.
Micro-droplets with various sizes might be formed in
this mixing step, and their absorption rates may differ by
droplet diameters. Despite differences in formulation,
the CL (12.2 L/h) and V (691 L) in our report were not
much different from those reported in a previous study
for IFN-α (7~8 L/h and 700~850 L, respectively) in
healthy subjects [19].
0     20         40         60        80       100
0 
   
   
 2
0 
   
  4
0 
   
  6
0 
   













0         20       40        60        80       100
0 
   
   
 2
0 
   
  4
0 
   
  6
0 














0         20        40       60        80      100
0 
   
   
   
1 
   
   
   
2 
   
   
  3
   
   








0             50           100         150
-2
   
 -
1 
   
 0
   
  1
   
  2
   
   
3 
   
 4
















5            10           15           20           25
5 
   
 1
0 
   
 1
5 
   
20
   
  2
5 















5          10         15          20         25
5 
   
 1
0 
   
 1
5 
   
 2
0 
   
25















5          10         15         20          25
0 
   
   
   
 2
   
   
   
  4
   
   
   








0         50      100      150     200     250
-2
   
   
  0
   
   
   
2 
   
   
  4
   
   
  6
















(A) IFN-α (B) Neopterin
Figure 4 Basic goodness of fit plots for PK and PD models. (A) and (B) are goodness of fit plots for PK (IFN-α) and PD (neopterin) models,
respectively. Black line, line of identity; gray line, LOESS (locally weighted regression) smooth line. The encircled dots in the PD plots represent
one outlier (ID No. 2) whose IFN-α concentrations were very low, but whose neopterin concentrations were rather higher.
Jeon et al. Journal of Translational Medicine 2013, 11:240 Page 7 of 9
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partment before the neopterin compartment gave better
outcome when compared with a simple turnover model.
The transit compartment for neopterin was used to
model data from monkeys [16], and we found that it is0                50             100             150             200
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solid line, individual predicted value.also useful in a human PK-PD model in this study. As
there are a few mechanistic models that tried to explain
little PD differences between dose groups (saturation of
responses) [16,20,21], we tested them for our neopterin
data in the preliminary PD model development step;0 
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Figure 6 Visual predictive checks of PK (Top) and PD (Bottom) models. One thousand datasets (24,000 virtual subjects) were simulated
using the final PK and PD parameter estimates. The simulated median (solid lines) and 75% prediction intervals (broken lines) were overlaid with
observed data. The two rightmost panels presenting medians of all dose groups show dose-linearity in PK, but not in PD.
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NONMEM. Neither the precursor turnover model [20]
that explained tolerance with depletion of precursor
molecules, nor the turnover feedback model [21] that
explained tolerance with negative feedback via a moder-
ator compartment provided acceptable parameter esti-
mates, and the basic goodness of fit plots were even
worse than those for the descriptive model of increasing
EC50. The inhibitory feedback model in monkeys [16]
also showed similar problems. Thus, we had to use the
concept of time-dependent attenuation of EC50 that did
not include mechanistic reasoning to describe our
neopterin response.
There are conflicting reports on saturation of neopterin
by IFN-α in patients. A report on patients with hairy cell
leukemia showed that neopterin responses and clinical
efficacies after low doses (0.5-0.8 MIU/day) were similar
to those after a conventional dose (3 MIU/day) in a 6-
month clinical trial [22]. In another clinical trial for a con-
trolled release formulation of IFN-α, increases in the mean
AUC of neopterin were marginal among the doses tested
(4.09 mM·h after 20 μg IFN-α and 6.61 mM·h after 320 μg
IFN-α) [23]. The forms of IFN-α used in those studies
[22,23] were non-pegylated forms, like the SR-IFN-α used
in this report; however, in phase I clinical trials of
pegylated IFN-α, neopterin responses were well correlated
with the doses used [24,25]. Such a discrepancy in
neopterin responses between non-pegylated and pegylated
IFN-α suggests that the polyethylene glycol tail attached
to IFN-α changed its PD parameters related to neopterin
production. To the best of our knowledge, although
pegylated formulations have long been used, it has neverbeen reported that their PD profile may be different from
that of non-pegylated forms.
Because neopterin is a frequently-used marker of cell-
mediated immunity, it can be used to monitor the de-
gree of immune activation in various clinical conditions,
including infections, autoimmune diseases, malignancies,
and other conditions [26]. Neopterin is also known to me-
diate the cytotoxic action of activated macrophages and
dendritic cells via interactions with reactive oxygen species
[27]. Thus, saturation of the neopterin response suggests
that the magnitude of cytotoxic action mediated by
neopterin may be similar regardless of the doses of IFN-α.
Conclusions
We developed a human PK-PD model revealing the sat-
urable neopterin response to IFN-α for the first time.
Our model suggests that the magnitude of cytotoxic ac-
tion mediated by neopterin may be similar regardless of
the doses of non-pegylated IFN-α.
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Additional file 1: Individual plasma concentration curves of SR-IFN-α
and neopterin.
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